The in vivo silencing of GOLPH3, in a combinatorial anti-tumor therapy, by using GOLPH3 siRNA and Gefitinib both conjugated to nanoparticles, inhibited EGFR signalling and glioma growth in the mouse model (Ye et al., 2019). The gene discussed is GOLPH3; the disease is neoplasm.